Agenus Inc.

AGEN Healthcare Biotechnology

Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.

6.04 0.64 −9.58%
Market cap
$301.7M
P/E
2.3×
Fwd P/E
4.1×
Dividend yield
—
F-score
4/9
Altman Z
−14.16
Beneish M
12.57
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Net Income
(3.08) (232.27) (257.44) (230.66) (28.72) (182.89) (111.56) (162.04) (120.69) (127.00)
Depreciation & Amortization
10.00 13.34 13.59 6.95 6.79 7.18 6.66 6.29 6.01 4.95
Non Cash Items (Other)
(111.44) 28.01 8.89 24.25 41.82 27.66 27.53 24.49 26.94 31.69
Accounts Receivable Change
(1.73) 25.34 (23.46) 0.12 (0.39) 16.19 (15.35) 0.20 10.22 (1.55)
Change in inventories
— — — — — — 0.06 0.02 0.01 0.09
Accounts Payable Change
23.50 2.01 21.37 6.49 10.82 2.77 (0.23) 5.37 1.65 0.42
Change in payables and accrued liability
4.50 0.14 20.61 2.03 (1.06) 3.83 7.10 3.30 (4.85) 18.28
Change in other assets and liabilities
1.26 5.80 (6.22) 15.43 (19.11) (13.83) 67.12 (8.72) (13.50) (6.75)
Other operating activities
(0.20) (0.69) (1.54) — — — — — — —
Operating Cash Flow
(77.19) (158.31) (224.20) (175.37) 10.15 (139.10) (18.68) (131.09) (94.23) (79.96)
Capital expenditures
0.35 (0.55) (6.59) (31.06) (28.16) (3.47) (4.66) (3.59) (3.00) (12.52)
Net Aquisitions
— — — (2.92) — (0.97) — — — —
Short Term Investments Change (Net)
— — (14.65) (24.63) (14.99) — — 0.00 5.06 30.12
Long-Term Investments Change (Net)
0.84 0.58 24.64 25.00 — — — — — —
Investing cash flow
1.19 0.03 3.40 (33.61) (43.15) (4.44) (4.66) (3.59) 2.06 17.60
Repayment/Issuance of Debt (Net)
2.35 9.52 (8.93) (0.49) (1.32) 2.97 (0.32) (162.13) 14.67 (0.14)
Equity Repurchase (Common, Net)
36.22 39.47 128.79 96.32 228.12 180.89 31.64 46.15 66.02 2.68
Equity Repurchase (Preffered, Net)
— — — — — — — 39.88 — —
Other financial activities
(1.97) 73.85 — — (1.54) — — 204.38 (0.15) (5.00)
Financing cash flow
36.59 122.84 119.87 95.83 225.26 183.86 31.32 128.29 80.54 (2.46)
Exchange Rate Adjustment
0.05 (0.26) (0.63) (0.10) (0.16) 0.38 0.77 (0.73) 0.36 (0.43)
Change in Cash
(39.36) (35.71) (101.56) (113.26) 192.10 40.70 8.75 (7.13) (11.26) (65.25)
Beginning Cash
44.07 79.78 181.34 294.60 102.51 61.81 53.05 60.19 71.45 136.70
Ending Cash
4.71 44.07 79.78 181.34 294.60 102.51 61.81 53.05 60.19 71.45
Stock Based Compensation
13.77 17.39 22.87 18.34 19.58 10.42 9.89 7.63 12.43 13.19
Dividends Paid (Common)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Cash/Marketcap
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Assets Liabilities Change (Total)
27.53 33.30 12.30 24.08 (9.74) 8.95 58.68 0.17 (6.48) 10.40
Investments Change (Net)
0.84 0.58 9.99 0.37 (14.99) — — — 5.06 30.12
Issuance/Purchase of Shares
36.22 39.47 128.79 96.32 228.12 180.89 31.64 86.03 66.02 2.68
Other line items
Revenue per Employee
1.41 0.33 0.40 0.18 0.67 0.25 0.46 0.13 0.17 0.09

Fold the line items

In millions of $ except per-share values · columns are period end dates